Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Terms Of The Trade: Dogs Of The Dow Investing Strategy

Benzinga.com  August 3, 2016

Mid-Afternoon Market Update: Crude Oil Down 1.5%; RetailMeNot Shares Gain On Strong Results

Benzinga.com  August 2, 2016

Following Pfizer's Q2 Results, Citi Says Investors Remain Focused On Potential Breakup

Benzinga.com  August 2, 2016

Oppenheimer Lowers Rating On Landstar Citing Low Visibility Into Business Conditions

Benzinga.com  August 2, 2016

Mid-Day Market Update: Dow Drops Over 100 Points; Avon Shares Surge Following Earnings Beat

Benzinga.com  August 2, 2016

Mid-Morning Market Update: Markets Open Lower; Pfizer Tops Q2 Views

Benzinga.com  August 2, 2016

It's Normal For Pfizer To Trade Down After Beating Estimates

Benzinga.com  August 2, 2016

PFIZER REPORTS SECOND-QUARTER 2016 RESULTS

Business Wire August 2, 2016

12 Stocks You Should Be Watching Today

Benzinga.com  August 2, 2016

Earnings Scheduled For August 2, 2016

Benzinga.com  August 2, 2016

How Can Pfizer's Drugs, Trials, And Acquisitions Grow Sales?

Benzinga.com  August 1, 2016

After GDP Surprise, Market Looks Ahead to More Earnings, July Jobs Report

Benzinga.com  August 1, 2016

Pfizer Aims to Become Industry Leader in Gene Therapy with Acquisition of Bamboo Therapeutics, Inc.

Business Wire August 1, 2016

Pfizer Announces Positive Top-Line Results from Pivotal Phase 3 Maintenance Trial of Oral XELJANZ® (Tofacitinib Citrate) in Ulcerative Colitis

Business Wire July 28, 2016

Pfizer And Western Oncolytics Reach Immuno-Oncology Research Collaboration

Benzinga.com  July 28, 2016

Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel Oncolytic Virus Technology

Business Wire July 28, 2016

18 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  July 27, 2016

Spark Therapeutics and Pfizer Announce Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity

GlobeNewswire July 25, 2016

Benzinga's M&A Chatter for Thursday July 21, 2016:

Benzinga.com  July 21, 2016

Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B

GlobeNewswire July 21, 2016